Follow DCH on Twitter! Like DCH on Facebook! Watch DCH Videos on YouTube! Keep up with DCH by visiting our newsroom!

Through our clinical trials program, patients who qualify can access other health care alternatives and investigational new drugs long before they are available on the open market. The Manderson Cancer Center jointly conducts clinical research with MD Anderson Cancer Center.

Lewis & Faye Manderson Cancer Center at DCH Regional Medical Center is a National Cancer Institute (NCI) Central Institutional Review Board Signatory Institution.  We are also an affiliate member of NRG Oncology which brings together the unique and complementary research areas of the National Surgical Adjuvant Breast and Bowel Project (NSABP), the Radiation Therapy Oncology Group (RTOG), and the Gynecologic Oncology Group (GOG). NRG Oncology builds upon their more than 150 years of cumulative research experience to conduct practice defining, multi-institutional clinical trials resulting in the improved survival and quality of life of patients with cancer. NRG Oncology has been awarded a grant by the National Cancer Institute (NCI) as a member of the NCI National Clinical Trials Network (NCTN).

During the months of January through December 2018, a total of 84 patents were accrued to trials.
Treatment/Interventional Trials - 3
Diagnostic Trials - 24
Prevention and Control Research - 34
Quality of Life and Economics of Care Studies - 23 is a searchable database which provides patients, family members and the public with information about current ongoing clinical research studies.

For any questions or to learn if you quality for a trial, please contact our Clinical Research Coordinator, Danielle Daniel, by phone at (205) 759-6237 or by email at

Below is a list of clinical trials that are currently offered at Manderson Cancer Center. We have attached the link for each study for ease in finding detailed information regarding these studies.

NRG Oncology

NRG-GU005 - Stereotactic Body Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Stage IIA-B Prostate Cancer

Principal Investigator - J. Curtis Tucker, MD

This randomized phase III trial studies how well stereotactic body radiation therapy works compared to intensity-modulated radiation therapy in treating patients with stage IIA-B prostate cancer. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Stereotactic body radiation therapy is a specialized radiation therapy that sends x-rays directly to the tumor using smaller doses over several days and may cause less damage to normal tissue. Stereotactic body radiation therapy may work better in treating patients with prostate cancer.

NRG-CC003 - A Randomized Phase III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer

Principal Investigator - J. Curtis Tucker, MD 

This trial studies how well whole-brain radiation therapy works and compares it with or without hippocampal avoidance in treating patients with small cell lung cancer.

MD Anderson Research Studies

2013-0609 – Biospecimen Banking and Biomarker Validation for Lung Cancer Early Detection in Cohort Receiving Low Dose Helical Computed Tomography Screening

Principal Investigator - J. Curtis Tucker, MD

This is a multicenter study led by MD Anderson to establish a Biospecimen repository from a cohort of current and former smokers who meet the criteria for low dose helical tomography (LDCT) screening.

At MD Anderson, they are developing new tests that may help improve lung cancer screening results. The Manderson Cancer Center is collaborating with MD Anderson in the Lung Cancer Early Detection Study. Click here for details.

External Beam Radiation to Eliminate Nominal Metastatic Disease (EXTEND): A Randomized Phase II Basket Trial Assessing the Efficacy of Upfront Local Consolidative Therapy (LCT) for Oligometastatic Disease

Principal Investigator – J. Curtis Tucker, MD

This phase II trial studies how well systemic therapy with or without local consolidative therapy work in treating patients with solid tumor that has spread to 1 site of other places in the body. Treatment with up-front local consolidative therapy may be better in helping to control the disease.



Lung Cancer Studies

INSIGHT – An Observational Study Assessing the Clinical Effectiveness of Veristrat® and Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Principal Investigator - John W. Dubay, MD, PhD

The primary purpose of this study is to assess the physician’s clinical practice patterns while using Veristrat in subjects with non-small cell lung cancer whose tumors are epidermal growth factor receptor (EGFR) wild-type or EGFR negative.

A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients With Unresected Stage I/II, Lymph-node Negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515)

Principal Investigator – John W. Dubay, MD, PhD

This is a Phase III, randomized, placebo-controlled, double-blind, multi-center study assessing the efficacy and safety of durvalumab versus placebo following standard of care SBRT in patients with unresected clinical Stage I/II lymph node-negative (T1 to T3N0M0) NSCLC.

Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Principal Investigator - John W. Dubay, MD, PhD

The purpose of this study is to observe and collect data for people with Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML)